BCM
SABS icon

Beryl Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Beryl Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,489
Closed -$1.86M – 389
2021
Q3 		$1.86M Buy
+18,489
New +$1.84M 0.13% 168

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Beryl Capital Management's SABS Position: Q4 2021 in Review

Beryl Capital Management sold out of SAB Biotherapeutics (SABS) in Q4 2021, closing a stake of 18,489 shares — an estimated $1.86M sold.

Beryl Capital Management first reported a position in SABS in Q3 2021 and held it in 1 quarter. The position peaked at $1.86M in Q3 2021. 34 funds tracked by Wall St. Rank hold SABS as of Q4 2021.

  • Beryl Capital Management reported no remaining SAB Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Beryl Capital Management sold 18,489 SAB Biotherapeutics shares in Q4 2021, an estimated $1.86M.
  • Beryl Capital Management first reported a position in SAB Biotherapeutics in Q3 2021 and held it in 1 quarter.
  • Beryl Capital Management's SAB Biotherapeutics position peaked at $1.86M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2021.

Based on Beryl Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.